Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Dmitriy Zamarin; Sven Walderich; Aliya Holland; Qin Zhou; Alexia E Iasonos; Jean M Torrisi; Taha Merghoub; Lewis F Chesebrough; Autumn S Mcdonnell; Jacqueline M Gallagher; Yanyun Li; Travis J Hollmann; Rachel N Grisham; Courtney L Erskine; Mathew S Block; Keith L Knutson; Roisin E O’Cearbhaill; Carol Aghajanian; Jason A Konner

doi:10.1136/jitc-2020-000829

Citation Tools

XML

Clinical trials monitor

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Zamarin D, Walderich S, Holland A, et al

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Journal for ImmunoTherapy of Cancer 2020;8:e000829. doi: 10.1136/jitc-2020-000829

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password